Enter the Dual and Triple Agonists To break through this ceiling, scientists began combining hormone targets: Dual Agonists (GLP-1 + GIP): Tirzepatide (Mounjaro, Zepbound) was the first commercially approved dual agonist
Therefore, to propose the opposite and suggest that glucagon agonism should be included in the pharmacotherapy of obesity and type 2 seems paradoxical
Among those who stopped, 24% cited side effects and 28% said they had reached their target weight
If your household income exceeds the thresholds by even $1, youre ineligible
By contrast, Beth Israel Deaconness Medical Center researchers have estimated that 129 million Americans could be eligible for semaglutide, the most popular GLP-1, for weight loss alone
What the clinical trials show The SURMOUNT clinical trial program is the largest body of evidence supporting tirzepatide for weight loss